|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, critical molecules such as C-X-C motif chemokine 12 (CXCL12), interleukin (IL)-8, colony-stimulating factor 3 (CSF3), and leukaemia inhibitory factor (LIF), were expressed at similar levels in BM-A and in primary human BM mesenchymal stromal cells (BM-MSC), whereas IL-3 was higher in BM-A.
|
28574591 |
2018 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Herein, we examined macrophages for their functions and responsiveness to IL-3 and GM-CSF in ENU-induced leukemia in BALB/c mice.
|
28039843 |
2017 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hence, we developed a novel strategy that combines both essential signals in 1 transgene by expressing the nonlymphoid hematopoietic growth factor receptor c-MPL (myeloproliferative leukemia), the receptor for thrombopoietin (TPO), in T cells. c-MPL signaling activates pathways shared with conventional costimulatory and cytokine receptor signaling.
|
29079582 |
2017 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found that the IL-3 receptor-α (IL-3Rα) is a promising candidate as an leukemia-initiating cell-specific antigen for FA-AML.
|
21330473 |
2011 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our results indicated that (1) the expression of TEL-FGFR3 but not DeltaHLH-TEL-FGFR3 resulted in efficient focus formation in NIH/3T3 cells and conferred interleukin 3 independence to Ba/F3 cells by a constitutive tyrosine kinase activity probably through oligomerization by the HLH domain of TEL; (2) although effector proteins including classical mitogen-activated protein kinase (MAPK), p38 MAPK, phosphatidylinositol 3-kinase (PI3-K), mammalian target or rapamycin (mTOR), signal transducer and activator of transcription 3 (STAT-3) and STAT-5 were activated in TEL-FGFR3 transformants, the growth of the transformants was inhibited by SU5402 (concentration that inhibits 50% [IC5)]=5 microM) and the PI3-K inhibitor, LY294002 (IC5)=10 microM) and wortmannin (IC50=5 microM), but not by U0126, SB203580, or rapamycin; and (3) injection of TEL-FGFR3 transformants induced lethal leukemia into syngeneic mice.
|
15514005 |
2005 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Granulocyte macrophage-colony stimulating factor and interleukin-3 increase expression of type II tumour necrosis factor receptor, increasing susceptibility to tumour necrosis factor-induced apoptosis. Control of leukaemia cell life/death switching.
|
15459750 |
2004 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To overcome multi-drug resistance, we engineered a diphtheria fusion protein by fusing human interleukin-3 (IL3) to a truncated form of diphtheria toxin (DT) with a (G4S)2 linker (L), expressed and purified the recombinant protein, and tested the cytotoxicity of the DTLIL3 molecule on human leukemias and normal progenitors.
|
10764142 |
2000 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Myeloproliferative disorder and leukaemia in mice induced by different classes of constitutive mutants of the human IL-3/IL-5/GM-CSF receptor common beta subunit.
|
10602472 |
1999 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data indicate that transgenic SCID mice expressing human IL-3 and GM-CSF provide a useful system for the study of human leukemia.
|
9714520 |
1998 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Deregulation of IL-3 receptor chain gene expression may provide a proliferative advantage to hematopoietic cells growing under conditions in which the cytokine is limiting and allow the development of a leukemia.
|
8642872 |
1996 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bone marrow cells were studied prior to and after 3 days of IL-3 administration to assess changes in overall and leukemic progenitor cell [leukemia colony-forming unit (CFU-L)] proliferation, and progenitor cell sensitivity to 1-betad-arabinofuranosylcytosine.
|
9815985 |
1995 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our data support the formulation that this subtype of leukemia may arise in part because of a chromosome translocation that activates the IL-3 gene, resulting in autocrine and paracrine growth effects.
|
2114933 |
1990 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Transcripts for IL3 mRNA were not detectable in these cells, nor in the K562 cell line, implying that autocrine secretion of IL3 was not the mechanism by which these leukemias were maintained.
|
2624775 |
1989 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The data suggest that activation of the IL-3 gene by the enhancer of the immunoglobulin heavy chain gene may play a central role in the pathogenesis of this leukemia and the associated eosinophilia.
|
2499362 |
1989 |